United Therapeutics (UTHR) has shown a remarkable performance, attracting attention from Wall Street analysts who have set their 12-month price targets. Based on insights from seven analysts over the past three months, the average price target for UTHR is $319.71, with the highest forecast at $400.00 and the lowest at $240.00. This average target suggests a modest 1.16% increase from its recent price of $316.04, indicating a generally positive but cautious outlook from analysts.
Looking ahead to the next quarter, the earnings per share (EPS) estimate for UTHR is $6.33, with a range between $5.67 and $7.47. This follows a previous quarter EPS of $6.17. Impressively, UTHR has exceeded its EPS estimates 100% of the time over the past 12 months, significantly outperforming its industry, which has a 57.26% beat rate in the same period. This consistent performance underscores the company’s robust financial health and operational efficiency.
In terms of sales, the forecast for the next quarter is $678.35 million, with estimates ranging from $641.80 million to $728.60 million. The previous quarter’s sales were $677.70 million. Similar to its earnings performance, UTHR has surpassed its sales estimates 100% of the time in the past year, while the broader industry achieved this 46.61% of the time. This consistent outperformance in both earnings and sales highlights UTHR’s strong market position and growth trajectory.
Evaluating UTHR’s market performance, the year-to-date return stands at an impressive 43.73%, compared to the S&P 500’s 14.57%. Over the past year, UTHR has delivered a 41.47% return, outpacing the S&P 500’s 24.52%. Over three years, UTHR’s return is 77.06%, while the S&P 500 posted a 31.16% return. The five-year performance is particularly noteworthy, with UTHR achieving a 305.49% return, significantly higher than the S&P 500’s 84.98%.
These metrics underscore UTHR’s exceptional growth and solid financial performance, making it a standout in its industry. The company’s ability to consistently beat both earnings and sales estimates, coupled with its strong stock performance relative to the broader market, positions it favorably for investors seeking robust growth prospects in the biopharmaceutical sector.
